The epithelial growth factor receptor (EGFR) has been a significant target for therapeutic development in glioblastoma owing to the high prevalence of EGFR amplification and its important role as a key survival signalling pathway [6,7]. The gene discussed is EGFR; the disease is glioblastoma.